Farmers Guardian
News
Word ‘milk’ banned for use in branding of plant-based products

Word ‘milk’ banned for use in branding of plant-based products

This Is Agriculture - Sponsored

This Is Agriculture - Sponsored

DataHub

DataHub

Auction Finder

Auction Finder

LAMMA 2020

LAMMA 2020

You are viewing your 1 free article

Register now to receive 2 free articles every 7 days or subscribe for unlimited access.

Subscribe | Register

Cereals 2019: Third-generation SDHI in the pipeline

A pipeline fungicide chemistry from Bayer offering 10 per cent better control of septoria is set to hit the market by 2022.

In Bayer trials, Iblon (isoflucypram) has shown 10 per cent better septoria control than existing SDHIs, and greater than 95 per cent control of yellow and brown rust.


Read More

Cereals 2019: High yielding feed wheat varieties stand up wellCereals 2019: High yielding feed wheat varieties stand up well
Farmers advised to adapt fungicide programmes to ensure protectionFarmers advised to adapt fungicide programmes to ensure protection
Fungicide performance continues to fallFungicide performance continues to fall
Programme targets fungicide applications based on riskProgramme targets fungicide applications based on risk

Hailing it as the first, third generation SDHI, Will Charlton, fungicide campaign manager at Bayer said: “The key difference that makes it third generation is it has a unique cyclopropyl unit.

“This gives it greater flexibility than existing SDHIs, so it has the ability to bind to the site of the pathogen you are trying to control better.”

 

Persistent

The product has also shown persistence in trials, added Mr Charlton.

“We have found this kind of disease control really hangs on and it is persistent in the crop.

“Often when you have fungicides with persistent characteristics you lose an element of curativity, and we don’t seem to be seeing that with this, so you get persistency without the drawback.”

Bayer is hoping for sales of Iblon to be approved by 2022.

TwitterFacebook
Post a Comment
To see comments and join in the conversation please log in.

Most Recent

Facebook
Twitter
RSS
Facebook
Twitter
RSS